ENDPOINTS

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Concentra Biosciences, the shell company from Tang Capital that tries to buy out struggling biotechs, has found another target, this time trying to throw a wrench in Acelyrin's merger plans with Alumis. Concentra delivered an ...

Feb 21, 2025 - 10:56
 0
Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger
Concentra Biosciences, the shell company from Tang Capital that tries to buy out struggling biotechs, has found another target, this time trying to throw a wrench in Acelyrin's merger plans with Alumis. Concentra delivered an ...
Read More

Tags:

Previous Article

Rolling back on climate actions may spell rise in preventable illness – study

Next Article

How do black holes 'leak' energy? Scientists have a new spin on the answer

Related Posts

Cerula Care raises $3.7M to support cancer patients’ mental health

Cerula Care raises $3.7M to support cancer patients’ me...

Feb 12, 2025  0

Post-Hoc: China tensions both help and hurt Illumina

Post-Hoc: China tensions both help and hurt Illumina

Feb 9, 2025  0

In single case, spinal muscular atrophy drug given before birth spared baby of symptoms

In single case, spinal muscular atrophy drug given befo...

Feb 20, 2025  0